Patents
US 8748476 B2: Darifenacin for use in the treatment of urgency induced by overactive bladder
- Granted
- 2014-06-10
- Filed
- 2009-03-04 application 12397433
- Type
- Utility · 5 claims
- Elsewhere
- Google Patents ↗ · USPTO patent document ↗ · USPTO Patent Center record ↗
Abstract
The invention provides the use of darifenacin, or a pharmaceutically acceptable derivative thereof, in the manufacture of a medicament for the reduction of urgency in patients suffering from overactive bladder.
Source: PVGPATDIS, file of 2026-04-10 (ipg140610.xml).
Assignees
| Assignee | Type | Place | Also on furp.org | Source |
|---|---|---|---|---|
| Warner Chilcott Company, LLC 27 patents | US company or organization | Fajardo, PR | WARNER CHILCOTT COMPANY, LLC State business registration EXACT high confidence: identical full name and state WARNER CHILCOTT PLC SEC filer FUZZY low confidence: same name (legal endings aside), one of each nationally | PVGPATDIS, file of 2026-04-10 |
Inventors
| Inventor | Place | Patents | Person page | Source |
|---|---|---|---|---|
| Enrico Colli | Sandwich, GB | 5 | PVGPATDIS, file of 2026-04-10 | |
| Paul Quinn | Sandwich, GB | 2 | PVGPATDIS, file of 2026-04-10 | |
| Dzelal Serdarevic | Sandwich, GB | 1 | PVGPATDIS, file of 2026-04-10 | |
| Larence Howard Skillern | Sandwich, GB | 1 | PVGPATDIS, file of 2026-04-10 |
CPC categories
| Subclass | Category | First group | Source |
|---|---|---|---|
| A61K | Preparations for medical, dental or toiletry purposes | A61K31/4025 | PVGPATDIS, file of 2026-04-10 |
| A61P | Specific therapeutic activity of chemical compounds or medicinal preparations | A61P7/12 | PVGPATDIS, file of 2026-04-10 |
Cooperative Patent Classification, as currently assigned (one row per subclass).
Assignments and security interests
| Recorded | What | From | To | Reel/frame | Source |
|---|---|---|---|---|---|
| 2018-02-22 | Correction Corrective assignment to correct the us patent no. 8,050,873 previously recorded on reel 040183 frame 0129. assignor(s) hereby confirms the assignment. | WARNER CHILCOTT COMPANY, LLC signed 2015-12-31 | ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED DUBLIN 17 | 45417/593 | PASDL, file of 2026-10-15 |
| 2016-09-29 | Assignment Assignment of assignor's interest | WARNER CHILCOTT COMPANY, LLC signed 2015-12-31 | ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED DUBLIN 17 | 40183/129 | PASDL, file of 2026-10-15 |
| 2013-10-31 | Release of security interest Release of security interest | BANK OF AMERICA, N.A., AS COLLATERAL AGENT signed 2013-10-01 | WARNER CHILCOTT COMPANY, LLC ROCKAWAY, NJ | 31531/538 | PASDL, file of 2026-10-15 |
| 2011-03-30 | Security interest Security interest Security agreement | WARNER CHILCOTT COMPANY LLC signed 2011-03-17 | BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT CHARLOTTE, NC | 26064/607 | PASDL, file of 2026-10-15 |
| 2010-10-27 | Assignment Assignment of assignor's interest | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. signed 2010-10-18 | WARNER CHILCOTT COMPANY, LLC FAJARDO, PR | 25204/49 | PASDL, file of 2026-10-15 |
Documents recorded with the USPTO Assignment Recordation Branch that list this patent. A security interest is a lender’s claim on the patent as collateral; a release ends it.
USPTO bulk data: PatentsView granted patents, disambiguated (PVGPATDIS) for patents, assignees, inventors, places and CPC categories; the USPTO Patent Assignment Dataset (ECORSEXC) for assignments and security interests. Patents filed in the last 20 years. No claims or full text. Links to other records are by name (and state): EXACT means the identical full name and state; FUZZY means a looser name match, with the confidence shown.